PTC Therapeutics (PTCT) Misses Q3 EPS by 12c

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.27), $0.12 worse than the analyst estimate of ($1.15). Revenue for the quarter came in at $9.78 million versus the consensus estimate of $9.88 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
• Carvana (CVNA) PT Lowered to $85 at RBC Capital